Inozyme Pharma Ownership | Who Owns Inozyme Pharma?

Inozyme Pharma Ownership Summary

Inozyme Pharma is owned by 72.69% institutional investors, 1.23% insiders, and 26.09% retail investors. Pivotal bioventure partners investment advisor is the largest institutional shareholder, holding 6.99% of INZY shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 3.46% of its assets in Inozyme Pharma shares.

INZY Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Inozyme Pharma	72.69%	1.23%	26.09%
Sector	Healthcare Stocks	479.67%	11.03%	-390.70%
Industry	Biotech Stocks	295.80%	10.97%	-206.77%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Pivotal bioventure partners investment advisor	4.49M	6.99%	$17.98M
Glazer capital	4.33M	6.74%	$17.32M
Sofinnova investments	4.28M	6.66%	$17.12M
Rock springs capital management lp	3.86M	6.10%	$10.70M
Blackrock	3.34M	5.41%	$14.91M
Trium capital llp	3.17M	4.94%	$12.69M
Vanguard group	2.63M	4.16%	$7.29M
Blackrock funding, inc. /de	2.66M	4.14%	$10.65M
Nea management company	2.44M	3.79%	$9.75M
Alpine associates management	2.19M	3.40%	$8.75M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Pivotal bioventure partners investment advisor	4.49M	11.14%	$17.98M
Trium capital llp	3.17M	3.16%	$12.69M
Knott david m jr	666.20K	1.21%	$2.66M
Sofinnova investments	4.28M	1.05%	$17.12M
Sanofi	443.25K	1.01%	$1.77M
Affinity asset advisors	1.75M	0.96%	$7.00M
Nea management company	2.44M	0.73%	$9.75M
Glazer capital	4.33M	0.62%	$17.32M
Oxford asset management llp	361.56K	0.52%	$1.45M
Alpine associates management	2.19M	0.47%	$8.75M

Top Buyers

Holder	Shares	% Assets	Change
Glazer capital	4.33M	0.62%	4.33M
Trium capital llp	3.17M	3.16%	3.17M
Alpine associates management	2.19M	0.47%	2.19M
Gabelli funds	1.46M	0.04%	1.46M
Omers administration	1.12M	0.04%	1.12M

Top Sellers

Holder	Shares	% Assets	Change
Adage capital partners gp	-	-	-5.16M
Samlyn capital	-	-	-3.26M
Eventide asset management	-	-	-2.22M
Affinity asset advisors	1.75M	0.96%	-2.12M
Samsara biocapital	-	-	-1.56M

New Positions

Holder	Shares	% Assets	Change	Value
Glazer capital	4.33M	0.62%	4.33M	$17.32M
Trium capital llp	3.17M	3.16%	3.17M	$12.69M
Alpine associates management	2.19M	0.47%	2.19M	$8.75M
Gabelli funds	1.46M	0.04%	1.46M	$5.83M
Omers administration	1.12M	0.04%	1.12M	$4.47M

Sold Out

Holder	Change
Ifp advisors	-1.00
Nelson, van denburg & campbell wealth management group	-9.00
Gamma investing	-27.00
Capital performance advisors llp	-35.00
Us bancorp \de\	-44.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2025	99	-5.71%	46,721,833	-10.83%	72	1.06%	43	-36.76%	28	75.00%
Dec 31, 2024	56	-37.78%	22,214,256	-59.31%	35	0.47%	38	-15.56%	6	-72.73%
Sep 30, 2024	89	-3.26%	54,577,497	1.39%	86	1.14%	44	-22.81%	22	15.79%
Jun 30, 2024	91	-	53,828,169	7.93%	87	0.94%	57	39.02%	18	-41.94%
Mar 31, 2024	91	9.64%	49,874,140	-0.33%	96	1.24%	41	-22.64%	31	106.67%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Eventide Healthcare & Life Sciences I	2.22M	3.46%	-1.91M
Vanguard Total Stock Mkt Idx Inv	1.69M	2.61%	-
Vanguard US Total Market Shares ETF	1.56M	2.43%	-
iShares Russell 2000 ETF	1.27M	1.97%	-
Fidelity Select Biotechnology	1.17M	1.81%	-
Vanguard Institutional Extnd Mkt Idx Tr	734.26K	1.14%	-
Fidelity Small Cap Index	545.22K	0.84%	14.59K
GAMCO Intl SICAV Merger Arbtrg I (USD)	495.63K	0.77%	495.63K
iShares Russell 2000 Value ETF	445.33K	0.69%	-
abrdn Life Sciences Investors	326.76K	0.51%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Apr 02, 2025	Treco Douglas A	CEO & Chairman	Sell	$7.85K
Apr 02, 2024	Treco Douglas A	CEO	Sell	$52.21K
Aug 01, 2023	Pivotal bioVenture Partners Fund I, L.P.	-	Buy	$3.43M
Aug 01, 2023	Pivotal bioVenture Partners Fund I, L.P.	-	Buy	$571.43K
Aug 01, 2023	Hopfner Robert Lorne	-	Buy	$3.43M

Insider Transactions Trends

Date	Buy	Sell
2025 Q3	-	-
2025 Q2	-	1
2025 Q1	-	-
2024 Q4	-	-
2024 Q3	-	-

INZY Ownership FAQ

Who Owns Inozyme Pharma?

Inozyme Pharma shareholders are primarily institutional investors at 72.69%, followed by 1.23% insiders and 26.08% retail investors. The average institutional ownership in Inozyme Pharma's industry, Biotech Stocks , is 295.80%, which Inozyme Pharma falls below.

Who owns the most shares of Inozyme Pharma?

Inozyme Pharma’s largest shareholders are Pivotal bioventure partners investment advisor (4.49M shares, 6.99%), Glazer capital (4.33M shares, 6.74%), and Sofinnova investments (4.28M shares, 6.66%). Together, they hold 20.39% of Inozyme Pharma’s total shares outstanding.

Does Blackrock own Inozyme Pharma?

Yes, BlackRock owns 5.41% of Inozyme Pharma, totaling 3.34M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 14.91M$. In the last quarter, BlackRock increased its holdings by 254.54K shares, a 8.24% change.

Who is Inozyme Pharma’s biggest shareholder by percentage of total assets invested?

Pivotal bioventure partners investment advisor is Inozyme Pharma’s biggest shareholder by percentage of total assets invested, with 11.14% of its assets in 4.49M Inozyme Pharma shares, valued at 17.98M$.

Who is the top mutual fund holder of Inozyme Pharma shares?

Eventide Healthcare & Life Sciences I is the top mutual fund holder of Inozyme Pharma shares, with 3.46% of its total shares outstanding invested in 2.22M Inozyme Pharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools